OpenAI is launching a specialized AI model for drug discovery and life sciences research

OpenAI has launched GPT-Rosalind, a specialized AI model for biology and drug discovery research, now available to qualified U.S. enterprise customers including Amgen, Moderna, and Thermo Fisher Scientific. The model handles complex scientific tasks like forming hypotheses and planning experiments, achieving top scores on bioinformatics benchmarks and outperforming human experts in RNA sequence prediction. The technology aims to accelerate the typically 10-15 year drug development process by helping researchers move faster through time-intensive scientific work.